• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

金丝桃苷在治疗阿尔茨海默病和帕金森病中的药理活性及治疗潜力:一项系统评价

Pharmacological activities and therapeutic potential of Hyperoside in the treatment of Alzheimer's and Parkinson's diseases: A systemic review.

作者信息

Yuan Jiayu, Dong Xiaoyu, Zhou Siyu, Nao Jianfei

机构信息

Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, PR China.

Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, PR China.

出版信息

Neuroscience. 2024 Dec 17;563:136-147. doi: 10.1016/j.neuroscience.2024.10.048. Epub 2024 Nov 1.

DOI:10.1016/j.neuroscience.2024.10.048
PMID:39489478
Abstract

Alzheimer's disease (AD) and Parkinson's disease (PD) are neurodegenerative disorders that significantly impact well-being. Hyperoside (HYP), a flavonoid found in various plant species, particularly within the genus Hypericin, exhibits diverse pharmacological properties. However, the precise mechanisms underlying the anti-AD and anti-PD effects of HYP remain unclear. This systematic review consolidated existing preclinical research on HYP by conducting a comprehensive literature survey and analysis. The objective was to corroborate the therapeutic efficacy of HYP in AD and PD models and to synthesize its potential therapeutic mechanisms. Searches were conducted in the PubMed, CNKI, and Web of Science databases. Reliability assessment of the 17 included studies confirmed the credibility of the mechanisms of action of HYP against AD and PD. We systematically assessed the neuroprotective potential of HYP in in vivo and in vitro models of AD and PD. Our findings indicated that HYP can mitigate, intervene in, and treat AD and PD animal models and associated cells through various mechanisms, including anti-oxidative, anti-inflammatory, anti-apoptotic, anti-Aβ aggregation, and cholinesterase inhibitory activities. Therefore, HYP potentially exerts anti-AD and anti-PD effects through diverse mechanisms, making it a promising candidate for therapeutic intervention in both AD and PD.

摘要

阿尔茨海默病(AD)和帕金森病(PD)是严重影响健康的神经退行性疾病。金丝桃苷(HYP)是一种存在于多种植物物种中的黄酮类化合物,特别是在金丝桃属植物中,具有多种药理特性。然而,HYP抗AD和抗PD作用的确切机制尚不清楚。本系统综述通过全面的文献调查和分析,整合了现有的关于HYP的临床前研究。目的是证实HYP在AD和PD模型中的治疗效果,并综合其潜在的治疗机制。在PubMed、CNKI和Web of Science数据库中进行了检索。对纳入的17项研究的可靠性评估证实了HYP对AD和PD作用机制的可信度。我们系统地评估了HYP在AD和PD体内和体外模型中的神经保护潜力。我们的研究结果表明,HYP可以通过多种机制减轻、干预和治疗AD和PD动物模型及相关细胞,包括抗氧化、抗炎、抗凋亡、抗Aβ聚集和胆碱酯酶抑制活性。因此,HYP可能通过多种机制发挥抗AD和抗PD作用,使其成为AD和PD治疗干预的有希望的候选药物。

相似文献

1
Pharmacological activities and therapeutic potential of Hyperoside in the treatment of Alzheimer's and Parkinson's diseases: A systemic review.金丝桃苷在治疗阿尔茨海默病和帕金森病中的药理活性及治疗潜力:一项系统评价
Neuroscience. 2024 Dec 17;563:136-147. doi: 10.1016/j.neuroscience.2024.10.048. Epub 2024 Nov 1.
2
Kaempferol, a potential neuroprotective agent in neurodegenerative diseases: From chemistry to medicine.山奈酚,一种神经退行性疾病潜在的神经保护剂:从化学到医学。
Biomed Pharmacother. 2023 Sep;165:115215. doi: 10.1016/j.biopha.2023.115215. Epub 2023 Jul 24.
3
Flavonoids as Therapeutic Agents in Alzheimer's and Parkinson's Diseases: A Systematic Review of Preclinical Evidences.黄酮类化合物作为阿尔茨海默病和帕金森病的治疗剂:临床前证据的系统评价。
Oxid Med Cell Longev. 2018 May 10;2018:7043213. doi: 10.1155/2018/7043213. eCollection 2018.
4
Kaempferol as a therapeutic agent in Alzheimer's disease: Evidence from preclinical studies.山奈酚作为阿尔茨海默病治疗剂的作用:来自临床前研究的证据。
Ageing Res Rev. 2023 Jun;87:101910. doi: 10.1016/j.arr.2023.101910. Epub 2023 Mar 15.
5
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.用于路易体痴呆、帕金森病痴呆及帕金森病认知障碍的胆碱酯酶抑制剂
Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD006504. doi: 10.1002/14651858.CD006504.pub2.
6
Lithium and disease modification: A systematic review and meta-analysis in Alzheimer's and Parkinson's disease.锂与疾病修饰:阿尔茨海默病和帕金森病的系统评价和荟萃分析。
Ageing Res Rev. 2024 Mar;95:102231. doi: 10.1016/j.arr.2024.102231. Epub 2024 Feb 15.
7
Selegiline for Alzheimer's disease.司来吉兰用于治疗阿尔茨海默病。
Cochrane Database Syst Rev. 2003(1):CD000442. doi: 10.1002/14651858.CD000442.
8
Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.在痴呆症患者中,停用或继续使用胆碱酯酶抑制剂、美金刚或两者。
Cochrane Database Syst Rev. 2021 Feb 3;2(2):CD009081. doi: 10.1002/14651858.CD009081.pub2.
9
Tissue Factor and Its Cerebrospinal Fluid Protein Profiles in Parkinson's Disease.组织因子及其在帕金森病中的脑脊液蛋白谱。
J Parkinsons Dis. 2024;14(7):1405-1416. doi: 10.3233/JPD-240115.
10
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.多奈哌齐、加兰他敏、利伐斯的明和美金刚治疗阿尔茨海默病的有效性和成本效果(技术评估第 111 号回顾):系统评价和经济模型。
Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210.